B-cell lymphoma – Medical News Asia

FDA Approves Truxima as Biosimilar to Rituxan

28 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Oncology, Chemotherapy, Targeted Therapies/by Stijn van den Borne, MSc

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

5 October 2018/0 Comments/in Medical News Asia, Haematology, Oncology, Immunotherapy/by scienterrific

TOKYO and BASKING RIDGE, N.J., October 3, 2018 /PRNewswire/ — The Japan Ministry of Health, Labour and Welfare (MHLW) granted the Orphan Drug designation to axicabtagene ciloleucel (KTE-C19, Daiichi Sankyo) for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBL), and transformed follicular lymphoma (TFL), which are all aggressive forms of non-Hodgkin lymphoma (NHL).

FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

14 June 2018/1 Comment/in US FDA Onc\Haem Approvals, Haematology, Oncology, Immunotherapy/by scienterrific

On June 13, 2018, the US FDA has granted accelerated approval to pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for the treatment of adult and pediatric patients with primary mediastinal large B-cell lymphoma (PMBCL), relapsed after two or more prior lines of prior therapy.

Tag Archive for: B-cell lymphoma